echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > [Science Sub-Journal] How to improve the "quality of life" of vaccinators?

    [Science Sub-Journal] How to improve the "quality of life" of vaccinators?

    • Last Update: 2021-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This article is original by Translational Medicine Network.
    Please indicate the source for reprinting.
    Author: John Introduction: Vaccines need to do more than fight the virus and survive.
    The ideal result is to prevent virus replication and reduce disease
    .

    To determine the most effective vaccine to combat this disease, it is necessary to establish a corresponding testing mechanism to collect vaccine response parameters to improve the "quality of life" of vaccinators
    .

    A new study published in "Science Translational Medicine" reports the protective effects of Ebola vaccine on five mucosal vaccine vectors based on human and avian paramyxoviruses
    .

    The study comprehensively describes the antibody response of each virus, helping to identify the elevated characteristics and functions of survivors, which can be used as immune-related substances for vaccine-induced protection
    .

    The paper published on July 14 is entitled "Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects.
    " This multi-year study focuses on whether all vaccines have protective effects and produce strong antibody responses.
    Led by Dr.
    Alexander Bukreyev of the University of Texas Medical Branch (UTMB) Galveston National Laboratory
    .

    The team also studied 139 different immune and vaccine response parameters to understand which parameters help improve the "quality of life" of vaccinators
    .

    Dr.
    Alexander Bukreyev said, “Testing during an outbreak is difficult because they are sporadic, but in order to determine the most effective vaccine against this disease, more research is needed
    .

    Establishing the characteristics of vaccine-generated immunity For vaccine design, evaluation and application, it is still very important
    .

    " The lead author of the paper, Dr.
    Michelle Meyer, a research scientist at UTMB, reported in this report the protection and antibody specificity induced by Ebola vaccine in non-human primates.
    Related to Fc-mediated effects, the result of the vaccine's immune effect in cynomolgus monkeys attacked by Ebola virus
    .

    The five mucosal vaccines tested have varying degrees of protection against death and disease, ranging from disease-free survival to only partial protection
    .

    Dr.
    Michelle Meyer pointed out that vaccines need to do more than just fight the virus to survive.
    The ideal result is to prevent virus replication and reduce disease
    .

    In order to assess the characteristics of antibodies that are relevant to protection and may predict protection, the team used a survival index in the analysis, which combines several Ebola parameters to correlate with improved infection outcomes
    .

    "Through in-depth characterization of the antibody response, we found that although all vaccines express the same antigen, they differ in many ways.
    The relevance of protection seems to be unique to a single vaccine platform
    .

    Our analysis defines RBD specificity Sex antibodies and Fc-mediated immune function are contributing factors to improved survival," Michelle Meyer said.
    "The lack of correlation with neutralizing antibody titers shows that traditional methods of predicting vaccine efficacy are not applicable to all vaccines
    .

    " In Sierra Leone During the recent Ebola outbreak in the Democratic Republic of Congo, more than 300,000 people were vaccinated
    .

    Michelle Meyer said that deciphering the immune response to protection-related vaccination is critical to predicting the efficacy of vaccines in humans
    .

    Reference materials: https://stm.
    sciencemag.
    org/content/13/602/eabg6128 Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment options
    .

    If you need health guidance, please go to a regular hospital for treatment
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.